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Environmental stimuli are known tocontribute topso-
riasis pathogenesis and that of other autoimmune
diseases, but the mechanisms are largely unknown.
Here we show that the aryl hydrocarbon receptor
(AhR), a transcription factor that senses environ-
mental stimuli, modulates pathology in psoriasis.
AhR-activating ligands reduced inflammation in the
lesional skin of psoriasis patients, whereas AhR
antagonists increased inflammation. Similarly, AhR
signaling via the endogenous ligand FICZ reduced
the inflammatory response in the imiquimod-induced
model of skin inflammation and AhR-deficient mice
exhibited a substantial exacerbation of the disease,
compared to AhR-sufficient controls. Nonhemato-
poietic cells, inparticular keratinocytes,were respon-
sible for this hyperinflammatory response, which
involved upregulation of AP-1 family members of
transcription factors. Thus, our data suggest a critical
role for AhR in the regulation of inflammatory re-
sponses and open the possibility for novel therapeu-
tic strategies in chronic inflammatory disorders.
INTRODUCTION
The skin is the organ most exposed to environmental insults,
and its complex cellular network constitutes an immunological
barrier that is crucial for the maintenance of homeostasis (Di
Meglio et al., 2011). It is therefore likely that inflammatory
disorders of the skin involve environmental factors. One such
disorder is plaque-type psoriasis, a disease with complex etio-
pathogenesis, characterized by epidermal hyperproliferation
and prominent immune infiltrates (Nestle et al., 2009). Cross-
talk between innate, adaptive, and epithelial or stromal cells,
such as keratinocytes and fibroblasts, underpins the disease
pathology (Lowes et al., 2013). A total of 36 disease-associatedloci have been identified as contributing to psoriasis (Tsoi et al.,
2012). Environmental risk factors, on the other hand, remain
less well defined on a mechanistic basis (Tagami, 1997).
Although no mouse model can fully recapitulate the develop-
ment and features of psoriasis (Gudjonsson et al., 2007), topical
application of the imiquimod (IMQ)-containing cream Aldara in-
duces a psoriasiform skin inflammation, which exhibits most of
the crucial traits (Swindell et al., 2011) including acanthosis,
parakeratosis, neutrophil recruitment, and involvement of the
IL-23-IL-17-IL-22 pathway (van der Fits et al., 2009), and is
thus increasingly used to dissect the mechanisms of psoriasis
pathogenesis.
In order to investigate the potential influence of environmental
factors on inflammatory skin disease, we have focused on the
ligand-dependent transcription factor aryl hydrocarbon receptor
(AhR), which responds to environmental stimuli and plays an
important role in the maintenance of intestinal homeostasis.
Work from our lab and others has shown that AhR-deficient
mice have an inherent weakness of the gut barrier (Kiss et al.,
2011; Lee et al., 2012; Li et al., 2011; Qiu et al., 2012). The
wide expression of AhR in several cell types of the skin suggests
a role for AhR signaling also at this barrier organ. The AhR is a
member of the bHLH-PAS family of transcription factors best
known for mediating the toxic effects of environmental contam-
inants such as TCDD (dioxin) and a range of other xenobiotic
substances. However, its evolutionary conservation from inver-
tebrate species onward points to a physiological role that does
not involve xenobiotic stimuli (Hahn et al., 2006; McMillan and
Bradfield, 2007). Endogenous ligands of AhR are found as in-
doles and flavonoids either of dietary origin (e.g., indolo[3,2-b]
carbazole, ICZ) (Bjeldanes et al., 1991; Gillner et al., 1985)
or, like the high-affinity ligand 6-formylindolo[3,2-b]carbazole
(FICZ), derived from tryptophanmetabolism via UV or visible light
exposure (Rannug and Fritsche, 2006), which has been found to
be physiologically relevant in human skin (Katiyar et al., 2000;
Rannug and Fritsche, 2006).
Combining the analysis of psoriasis patient skin biopsies with
that of a mouse model of psoriasiform inflammation, we showed
that AhR signaling in nonhematopoietic cells plays a central role
in preventing excessive skin inflammation.Immunity 40, 989–1001, June 19, 2014 ª2014 The Authors 989
Figure 1. AhR Ligation in Human Skin
Biopsies Modulates Psoriasis-Relevant
Genes
Lesional (L) and nonlesional (NL) skin biopsies
from eight psoriasis patients were quartered: one
quarter of each was used as baseline and the re-
maining three quarters were cultured with either
vehicle control, the AhR agonist FICZ, or the AhR
antagonist CH-223191 for 16 hr. Whole-skin
biopsies from five healthy donors (H) were pro-
cessed in the same way. All samples were sub-
jected to RNA sequencing.
(A) Venn diagram showing genes significantly
regulated by either FICZ or CH-223191 in at
least one out of the three tissue types analyzed
(L, NL, H).
(B) Heat map of known AhR-target genes
modulated by FICZ and CH-223191. Color in-
dicates mean fold change, with green represent-
ing decreased and red increased gene expression.
(C) Heat map of genes belonging to the ‘‘psoriasis
transcriptome’’ (upregulated genes shown in bold)
and modulated by FICZ or CH-223191. Genes are
sorted by decreasing fold change for agonist
effect on L skin.
(D) qPCR validation for six top modulated genes
downregulated in L skin by agonist-induced AhR
activation. Box and whiskers denoting minimum
and maximum values are shown. Wilcoxon signed
rank test (for CMPK2) or paired t test (all other
genes) was performed.
(E) qPCR validation of six top modulated genes
upregulated in NL skin by antagonist-induced AhR
inhibition. Box and whiskers denoting minimum
and maximum values are shown. Wilcoxon signed
rank test was performed.
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AhR Ligation in Human Skin Biopsies Modulates
Psoriasis-Relevant Genes
In order to addresswhether the AhR pathway has a role in human
skin pathology, we investigated whether AhR activation via the
agonist FICZ or inhibition via the antagonist CH-223191 (Kim
et al., 2006) would cause transcriptional changes in psoriasis-
related genes. Full-thickness skin biopsies were obtained from
lesional (L) and uninvolved nonlesional (NL) skin of eight psoriatic
patients not receiving any systemic treatment and from healthy
human subjects (N) serving as control (Table S1 available online).
The biopsies were quartered and one segment was reserved for
RNA sequencing without any treatment. The remaining three
quarters were cultured with DMSO (vehicle control), FICZ, or
CH-223191 for 16 hr. After treatment all samples were subjected
to RNA sequencing. Analysis of the untreated L and NL psoriasis
skin samples provided us with genes differentially regulated in
the two tissue types, or the ‘‘psoriasis transcriptome.’’ The top
25 most significantly regulated genes (Table S2) were in keeping
with published data sets (Gudjonsson et al., 2010; Tian et al.,
2012) with several members of the S100 protein family signifi-
cantly upregulated in L versus NL skin. Next, we identified the990 Immunity 40, 989–1001, June 19, 2014 ª2014 The Authorstranscriptional changes induced by exposure to AhR agonist
or antagonist. A flowchart describing step by step our filtering
criteria is shown in Figure S1. We identified 884 AhR-modulated
genes, defined as genes significantly regulated by either the
agonist or the antagonist in at least one out of the three tissue
types analyzed (L, NL, H) (Figure 1A). As expected, expression
of CYP1A and CYP1B1, well-characterized AhR-target genes,
were found to be highly upregulated in the presence of agonist
and downregulated by the antagonist in all three tissue types
(Figure 1B). The list of AhR-modulated genes was reduced to
41 genes belonging to the ‘‘psoriasis transcriptome,’’ which
were mainly upregulated in untreated L skin (Figure 1C, psoria-
sis-upregulated genes are shown in bold, and Table S3). Out
of these, 29 (70%) were reduced after FICZ-induced AhR activa-
tion. This effect was most prominent in L skin, as confirmed by
qRT-PCR showing a downward trend for the top five regulated
genes (IFIT, RSAD2, IFIT3, CMPK2,MX2), which reached statis-
tical significance for IFIT1 (Figure 1D). Conversely, treatment
with AhR antagonist was able to increase expression of these
genes in NL skin, with statistically significant fold change in-
crease for all genes validated by qRT-PCR (Figure 1E). Ingenuity
pathway analysis showed that 26 out of 41 psoriasis-relevant
genesmodulated by AhR belong to the type I and II IFN pathway,
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AhR in Skin Inflammationwhich is known to be upregulated in psoriasis (Figure S1). Thus,
AhR appears to play a critical role in modulating the severity of
psoriasis. In order to study the influence of AhR in more detail,
we employed the mouse model of IMQ-induced psoriasiform
inflammation.
AhR-Deficient Mice Develop Exacerbated IMQ-Induced
Psoriasiform Skin Inflammation
Treatment of AhR-deficient (Ahr/) and AhR-heterozygous
littermate control (Ahr+/) mice with IMQ over a 5-day period re-
sulted in scaling and parakeratosis of the Stratum corneum and
epidermal acanthosis and widespread inflammatory infiltrates,
as seen by visual inspection (Figure S2A) and in H&E-stained
skin sections (Figure 2A). Untreated skin of Ahr/ and Ahr+/
littermate controls was histologically indistinguishable, but
upon treatment the thickening of both epidermis and Stratum
corneum was significantly increased in Ahr/ mice (Figure 2B).
Nevertheless, the exacerbated skin pathology elicited by IMQ
treatment in the absence of AhR signaling abated after termina-
tion of treatment. Quantitative RT-PCR analysis of inflamed
skin from Ahr/mice revealed statistically significant increased
expression of growth factors and chemokines involved in
neutrophil attraction (Csf2, Csf3, Cxcl1, Cxcl5) and of antimicro-
bial peptides typically present in psoriasis lesions (S100a7a,
S100a8), as well as reduced expression of the keratinocyte dif-
ferentiation marker Krt10 (Figure 2C). Moreover, mRNA expres-
sion of a number of proinflammatory cytokines, including Il17a,
Il17c, Il23, Il22, and Il1b, which are crucially involved in psoriatic
skin inflammation (Di Cesare et al., 2009; van der Fits et al.,
2009), was significantly increased in the skin of Ahr-deficient
mice (Figure 2D). Upregulation of Il1b mRNA in Ahr/ mice
preceded that of IL-17 (Figure S2B) and remained increased at
protein level on day 5 (Figure S2C). Although there was substan-
tial infiltration of T cells producing IL-17 cell type cytokines, the
majority of which were gd T cells (Figure S2D) as previously re-
ported (Pantelyushin et al., 2012), absolute numbers of IL-17-
and IL-22-producing CD4 and gd T cells did not differ between
Ahr+/ and Ahr/mice (Figure 2E). In agreement with our earlier
finding (Martin et al., 2009), AhR-deficient gd T cells appear to
make more IL-17 on a per cell basis, thus accounting for the in-
crease in IL-17 observed in the skin of Ahr/mice (Figures S2E
andS2F). In linewith the increase in neutrophil-recruiting chemo-
kines, there was significantly more neutrophil infiltration into the
skin inAhr/mice (Figure 2F), whereas the number of bothmac-
rophages and dendritic cells (DCs) did not differ between the two
groups (Figure S2G), and we did not observe substantial infiltra-
tion of IL-17-producing CD8 T cells or innate lymphoid cells (data
not shown). Thus, absence of AhR signaling led to heightened
inflammation and exacerbated skin pathology. This phenotype
was not restricted to the psoriasisform inflammation induced
by IMQ, but also extended to amodel of delayed-type hypersen-
sitivity (DTH) skin reactions in Ahr-deficient mice, which showed
enhanced neutrophil infiltration and increased inflammatory che-
mokine expression (data not shown).
AhR Activation by FICZ Ameliorates IMQ-Induced
Psoriasiform Skin Inflammation
Next, we askedwhether deliberate triggering of the AhR pathway
would have a beneficial effect on skin pathology as seen in hu-man psoriatic skin. To this end, wild-typemice received intraper-
itoneal injections of either FICZ or olive oil (vehicle control) daily
during the course of IMQ treatment. FICZ administration upregu-
lated expression of Cyp1a1 mRNA in the skin, as compared to
mice receiving vehicle only (Figure 3A), and resulted in attenu-
ated psoriasiform skin inflammation, with milder parakeratosis
and cell infiltration (Figure 3B), statistically significant reduction
in epidermal and scale thickness (Figure 3C), and reduced
expression of proinflammatory mediators (Figures 3D and S3).
Thus, activation of the AhR pathway in vivo results in ameliora-
tion of psoriasiform skin pathology.
AhR Deficiency in Nonhematopoietic Cells Causes
Exacerbated Skin Inflammation
In order to identify the AhR-expressing cell type responsible
for the hyperinflammatory skin response seen in Ahr/ mice,
we generated mice with conditional deletion of AhR in distinct
immune cell subsets in the skin. Ahrfl/ Cd11c.Cre or Ahrfl/
Rag1.Cremice, in which AhR is deleted in DCs and somemacro-
phage subsets or in T and B cells, respectively, were treated with
IMQ in order to address the contribution of these cells to the
exacerbated skin inflammation seen in complete AhR deficiency.
qPCR analysis confirmed the deletion of AhR in DCs or in T cells
of thesemice (Figures S4A and S4C). Lack of AhR in DCs ormac-
rophages did not result in increased inflammation above that
observed in control Ahrfl/+ Cd11c.Cre mice (Figures 4A–4D and
S4B). Lack of AhR in T and B cells resulted in increased skin
acanthosis and reduced keratinocyte differentiation, but no
difference in skin scaling, expression of themajority of inflamma-
torymediators, or number of neutrophils when compared to con-
trol mice (Figures 4E–4H and S4D). These observations ruled out
a role for DCs or macrophages in driving the exacerbated skin
inflammation seen in Ahr/ mice, but left open the possibility
that activation of the AhR pathway in T or B lymphocytes is
important for skin homeostasis.
Next, we addressed the contribution of Ahr deficiency in non-
hematopoietic skin cells such as keratinocytes and fibroblasts.
We generated bone marrow (BM) chimeras in which hematopoi-
etic cells were of wild-type origin, whereas the nonhematopoietic
compartment was either Ahr/ (rAhR/) or wild-type (rAhR+/+)
by reconstituting Ahr/Rag1/ and control Ahr+/+ Rag1/
hosts with BM from Ahr wild-type donors. AhR deficiency
in the nonhematopoietic compartment recapitulated the hyper-
inflammatory phenotype of full AhR/ mice with exacerbated
epidermal pathology (Figures 5A and 5B), increased neutrophil
recruitment (Figure 5C), overexpression of inflammatory
markers, and reduced keratinocyte differentiation (Figure 5D).
In contrast, expression of both IL-17 and IL-22 was not different
in the two experimental groups, making it unlikely that these cy-
tokines are responsible for the hyperinflammatory skin response
of Ahr/ mice. In line with this, treatment of Ahr/ mice with
neutralizing antibody to IL-17A did not improve their exagger-
ated response (Figures S4E–S4G).
BM chimeras in which the nonhematopoietic cells were
of wild-type origin, whereas the hematopoietic compartment
was either Ahr+/ (dAhR+/) or Ahr deficient (dAhR/), did not
show increased inflammation above that observed in control
mice (Figures 5E–5G). Disease severity was not increased
in Ahr/Rag1/ versus Ahr+/ Rag1/ (data not shown),Immunity 40, 989–1001, June 19, 2014 ª2014 The Authors 991
Figure 2. Exacerbated Skin Inflammation in Ahr-Deficient Mice
(A) Representative images of H&E staining of skin sections from untreated (baseline) and IMQ-treatedAhr+/ (open circles) and Ahr/ (filled circles) mice at day 5
(scale bars represent 100 mm).
(B) Quantification of epidermal (left) and scale thickness (right) of Ahr+/ (open circles) and Ahr/ (filled circles) at different time points after initiation of IMQ
treatment.
(legend continued on next page)
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Figure 3. Skin AhR Activation by FICZ Ameliorates IMQ-Induced Psoriasis-like Skin Inflammation
(A) Cyp1a1 expression in skin of IMQ-treated C57BL/6 mice receiving vehicle (black bars) or FICZ (white bars) i.p. for 6 days.
(B) H&E staining of skin sections (day 6) from IMQ-treated C57BL/6 mice receiving vehicle or FICZ.
(C) Quantification of epidermal (left) and scale thickness (right) at day 6 of vehicle-treated (black bars) or FICZ-treated (white bars) mice.
(D) mRNA expression of psoriasis-relevant genes in whole skin from IMQ-treated C57BL/6 mice receiving vehicle (black bars) or FICZ (white bars).
Plots show mean ± SEM; n = 5 mice per group. Results from one representative experiment of three independent experiments are shown. *p < 0.05, **p < 0.01.
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AhR in Skin Inflammationemphasizing that the cross-talk between adaptive immune cells
and epidermal cells is essential for the exacerbated pathology
observed in Ahr-deficient mice. Therefore, AhR deficiency in
the nonhematopoietic skin compartment is necessary and suffi-
cient for the development of an exacerbated psoriasiform skin
response in the presence of a fully functioning adaptive immune
system.
AhR-Deficient Keratinocytes Show Exacerbated
Response to Proinflammatory Cytokines
Our results showed that physiological AhR activation can
ameliorate the inflammatory program in nonhematopoietic
skin cells. In order to discriminate between the inflammatory
response of epithelial and stromal cells, we assessed the
response of Ahr-sufficient or -deficient keratinocytes to the im-
mune activators produced in the early phase of IMQ-induced
skin inflammation. We therefore stimulated keratinocytes
from Ahr+/ and Ahr/ mice in vitro with conditioned medium
(CM) from in-vitro-reactivated skin cells obtained from either
naive (nCM) or 2-day IMQ-treated (iCM) wild-type mice. Ahr/
keratinocytes responded to iCM by significantly overex-(C and D) mRNA expression of proinflammatory mediators and keratinocyte dif
circles) mice at day 5.
(E) Number of CD4 and gd T cells expressing IL-17 (left) and IL-22 (right) per cm2 s
intracellular cytokine staining.
(F) Number of neutrophils (3105) per cm2 of skin.
Plots showmean ± SEM, n = 3–5 mice per group or mean and values of individual
independent experiments are shown. *p < 0.05, **p < 0.01, ***p < 0.001, and ****pressing proinflammatory cytokine and chemokine mRNA as
compared to heterozygous controls (Figure 6A). Ahr/ fibro-
blasts also displayed an increased response as compared to
their Ahr+/ counterparts, although to a lesser extent (data
not shown). IL-1b is one of the mediators in the early phase
of the IMQ-induced skin inflammation model (Walter et al.,
2013), and this cytokine was overrepresented in the condi-
tioned medium obtained from wild-type IMQ-treated mice,
far exceeding other cytokines tested such as TNF, IL-23, and
IL-17A (data not shown). Indeed, recombinant IL-1b could
replace iCM, causing comparable upregulation of inflammatory
markers on keratinocytes (Figure 6B), whereas neutralizing
IL-1b abrogated the proinflammatory response to the skin
cell conditioned medium (Figure S5A). In addition, we also
found increased expression of Il1r1 in ex vivo Ahr/ keratino-
cytes (Figure 6C).
Furthermore, similar hyperresponsiveness was found in hu-
man keratinocytes upon knockdown of AHR expression. Thus,
normal primary keratinocytes in which AHR expression was
reduced by AHR-SiRNA showed overexpression of proinflam-
matory mediators compared to keratinocytes transfected withferentiation marker in whole skin from Ahr+/ (open circles) and Ahr/ (filled
kin of IMQ-treated Ahr+/ (white bars) and Ahr/ (black bars) mice obtained by
mice, n = 8 mice per group. Results from one representative experiment of two
p < 0.0001.
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Figure 4. AhR Deficiency in Dendritic Cells or in T and B Cells Does Not Recapitulate the Phenotype of Ahr–/– Mice
(A) Representative images of H&E staining of skin sections from imiquimod-treated Ahrfl/+ or Ahrfl/ Cd11c.Cre mice at day 5 (scale bars represent 100 mm).
(B) Quantification of epidermal (left) and scale thickness (right) at day 5.
(C) Number of neutrophils per cm2 of skin as determined by FACS analysis of Ly6G+ cells.
(D) mRNA expression of psoriasis-relevant genes in whole skin from Ahrfl/+ (white bars) or Ahrfl/ Cd11c.Cre mice (black bars) at day 5.
(E) Representative images of H&E staining of skin sections from imiquimod-treated Ahrfl/+ or Ahrfl/ Rag1.Cre mice (scale bars represent 100 mm).
(F) Quantification of epidermal (left) and scale thickness (right) at day 5.
(G) Number of neutrophils per cm2 of skin as determined by FACS analysis of Ly6G+ cells.
(H) mRNA expression of psoriasis -relevant genes in whole skin from Ahrfl/+ (white bars) or Ahrfl/ Rag1.Cre mice (black bars) at day 5.
Plots show mean + SEM; n = 4–6 mice per group. Results from one representative experiment of two independent experiments per mouse strain are shown.
*p < 0.05, **p < 0.01, and ***p < 0.001.
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Figure 5. Lack of AhR in Nonhematopoietic Cells Recapitulates Exacerbated Skin Inflammation of Ahr–/– Mice
(A) Representative images of H&E staining of skin sections from IMQ-treated Ahr+/+ / Ahr+/+Rag1/ (rAhR+/+) or Ahr+/+ / Ahr/Rag1/ (rAhR/) BM
chimeras (scale bars represent 100 mm).
(B) Quantification of epidermal (left) and scale thickness (right) of rAhR+/+ (white bars) or rAhR/ (black bars) chimeras at day 5.
(C) Number of neutrophils per cm2 of skin.
(D) mRNA expression of psoriasis-relevant genes in whole skin from rAhR+/+ (white bars) or rAhR/ (black bars) chimeras at day 5.
(E) Quantification of epidermal (left) and scale thickness (right) ofAhr+//Ahr+/+Rag1/ (dAhR+/, white bars) orAhr//Ahr+/+Rag1/ (dAhR/, black bars)
chimeras at day 5.
(F) Number of neutrophils per cm2 of skin.
(G) mRNA expression of psoriasis-relevant genes in whole skin from dAhR+/ (white bars) or dAhR/ (black bars) chimeras at day 5.
Plots show mean + SEM; n = 5–7 mice per group. Results from one representative experiment of two independent experiments per each set of chimeras are
shown. *p < 0.05, **p < 0.01, and ***p < 0.001.
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results were also obtained in the spontaneously transformed
keratinocyte cell line HaCaT, in which AHR had been stablysilenced (AHR-silenced HaCaT), when compared to cells trans-
fected with an empty vector (EV-HaCaT) (Figure 6E; Fritsche
et al., 2007).Immunity 40, 989–1001, June 19, 2014 ª2014 The Authors 995
Figure 6. Ahr-Deficient Murine and Human Keratinocytes Show Exacerbated Response to Inflammatory Stimuli
(A) mRNA expression of proinflammatory mediators in Ahr+/ (white bars) and Ahr/ (black bars) murine keratinocytes stimulated for 24 hr with conditioned
medium nCM and iCM. Data are expressed as fold change over stimulation with iCM over nCM medium.
(B) mRNA expression of proinflammatory mediators in Ahr+/ (white bars) and Ahr/ (black bars) murine keratinocytes stimulated for 24 hr with recombinant
IL-1b (10 ng/ml). Data expressed as fold change over medium control.
(C) Il1r1 mRNA expression in unstimulated murine primary keratinocytes from Ahr+/ (white bars) and Ahr/ (black bars) mice.
(D) mRNA expression of proinflammatory mediators in human primary keratinocytes, transiently transfected for 48 hr with a nontargeting control SiRNA (cSiRNA,
white bars) or in which AhR was transiently silenced (AhR-SiRNA, black bars), and stimulated for further 24 hr with human recombinant IL-1b (10 ng/ml).
(E) mRNA expression of proinflammatory mediators in human keratinocytes HaCaT cell lines, stable transfected with an empty vector (EV-HaCaT, white bars), or
in which AhR had been stable silenced (AhR-silencedHaCaT, black bars), and stimulated for 24 hr with human recombinant IL-1b. Data expressed as fold change
over medium control.
Results from one representative experiment of two or three independent experiments are shown. Plots show mean ± SEM; n = 3–6 wells per group. *p < 0.05,
**p < 0.01, and ****p < 0.0001.
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skin cells, particularly keratinocytes, require AhR to control
expression of inflammatory mediators in response to inflamma-
tory stimuli, such as IL-1b. Therefore we conclude that AhR defi-
ciency in both epithelial and stromal cells results in a cell-intrinsic
overreaction to inflammatory stimuli, leading to exacerbated skin
pathology in vivo.
AhR Modulates JunB Expression in Keratinocytes
The AhR is thought to be involved in extensive cross-talk with
other transcription factors and multiple signaling pathways,
which makes the systematic analysis of physiological inter-
actions a challenging task. To gain more insights about how
AhR modulates keratinocyte activation, we focused on the early
phase of the IMQ treatment and performed microarray analysis
of whole skin from Ahr+/ or Ahr/ mice treated for 2 days with
IMQ. By using Ingenuity pathway analysis, we identified a num-
ber of psoriasis-annotated transcription factors regulated by the
IMQ treatment and found an overrepresentation of the activator
protein-1 (AP-1) family of transcription factors (Figure 7A). AP-1
regulates a range of biological mechanisms, including keratino-996 Immunity 40, 989–1001, June 19, 2014 ª2014 The Authorscyte differentiation and proliferation (Bata-Csorgo and Szell,
2012) and epithelial cell immune activation (Wang et al., 2013).
Also, the AP-1 family member JunB, whose activity is transcrip-
tionally regulated (Karin et al., 1997), is increased in psoriasis
and localizes to keratinocyte nuclei within the hyperplastic
epidermis of psoriasis lesions (Haider et al., 2006; Swindell
et al., 2013). We found the expression of Junb significantly
increased in the skin of Ahr/ mice as compared to Ahr+/
mice in the early phase (day 2) of IMQ-induced inflammation
(Figure 7B), whereas whole skin isolated from FICZ-treated
wild-type mice showed reduced Junb levels (Figure 7C), sug-
gesting that AhR can control the expression of this AP-1 family
member. Moreover, isolated keratinocytes from Ahr/ mice
significantly upregulated JunB protein (Figure 7D) and mRNA
(Figure S6) in response to IL-1b and iCM. Finally, inhibition of
the AP-1 pathway with the inhibitor Tanshinone IIA (Tseng
et al., 2013) resulted in decreased expression of proinflamma-
tory genes in Ahr/ keratinocytes (Figure 7E). These findings
show that AhR controls the expression of other transcription
factors responsible for establishing an inflammatory transcrip-
tional program in keratinocytes, e.g., AP-1, and thus constitutes
Figure 7. Ahr-Deficient Keratinocytes Display Increased Levels of JunB
(A) Heat map visualization of IMQ-regulated, psoriasis-annotated transcription factors in whole skin of Ahr+/ and Ahr/mice on day 2 of IMQ treatment. Green
color indicates decreased and red color increased gene expression, expressed as mean fold change in IMQ-treated as compared to corresponding untreated
mice. AP-1 family transcription factors aremarked in bold. Asterisks indicate genes differentially expressed inAhr/ versusAhr+/ skin at day 2 of IMQ treatment.
(B) Time course of Junb mRNA expression in whole skin from Ahr+/ (open circles) and Ahr/ (filled circles) mice.
(C) Junb mRNA expression in whole skin from IMQ-treated C57BL/6 mice receiving vehicle (black bars) or FICZ (white bars) at day 6.
(D) Immunoblot showing JunB protein levels in Ahr+/ (white bars) and Ahr/ (black bars) murine keratinocytes stimulated for 4 hr with recombinant IL-1b
(10 ng/ml). Values denotes JunB/GAPDH densitometry ratio.
(E) mRNA expression of Csf2 and Csf3 in murine keratinocytes stimulated for 24 hr with recombinant IL-1b (10 ng/ml) with or without Tanshinone (1 mM). Data
expressed as fold change over medium control.
Plots show mean ± SEM; n = 3–6 wells or mice per group. Results from one representative experiment of two independent experiments are shown. **p < 0.01,
***p < 0.001, and ****p < 0.0001.
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processes.
DISCUSSION
The contribution of environmental factors to the pathogenesis of
inflammatory disorders is well known, but the nature and mode
of action of such stimuli remains ill defined. We show here that
environmental signals transmitted via AhR dampen the inflam-
matory response in both mouse and human skin. Lack of Ahr
causes hyperinflammation, whereas deliberate AhR activation
with the endogenous ligand FICZ ameliorates the inflammatoryprofile in both human psoriasis samples and the mouse model
of psoriasiform skin inflammation. Our data emphasize the
cross-talk between cells of the immune system and nonhemato-
poetic cells during inflammation, and it is now widely recognized
that such interactions crucially underpin both the homeostasis of
the skin environment and its dysregulation in diseases such as
psoriasis (Di Meglio et al., 2011; Lowes et al., 2013). The focus
for therapeutic intervention in psoriasis is currently on modu-
lating inflammatory immune parameters such as IL-17, IL-12,
IL-23, or TNF (Lowes et al., 2013), which are the immune drivers
of skin pathology in both human disease and the mouse model.
In agreement with the literature (Pantelyushin et al., 2012; VanImmunity 40, 989–1001, June 19, 2014 ª2014 The Authors 997
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AhR in Skin InflammationBelle et al., 2012; van der Fits et al., 2009), we found many
parameters linked to the IL-17 program highly upregulated in
IMQ-induced skin inflammation and even further exacerbated
in Ahr/ mice. However, our data show that immune cells are
not the main cause for the hyperreactivity observed in Ahr-defi-
cient mice. Instead, the response of nonhematopoietic skin cells,
primarily keratinocytes but also skin fibroblasts, to inflammatory
stimuli was severely dysregulated in the absence of AhR. How-
ever, in vivo blockade of this cytokine was not sufficient to
dampen the exaggerated skin response of Ahr-deficient mice
(data not shown), suggesting that multiple inflammatory path-
ways are involved.
It was important to delineate contributions by different cell
types because it was suggested, for instance, that the epidermal
TCR-gd population, which interacts with keratinocytes (Chodac-
zek et al., 2012) and is absent in Ahr/mice (Kadow et al., 2011;
Li et al., 2011), may fulfil protective functions in cutaneous
inflammation (Girardi et al., 2006; Kadow et al., 2011). However,
mice with selective Ahr deficiency resulting from Rag1 Cre-
mediated deletion also lack this population, yet did not display
the widespread overreaction seen in Ahr/ skin although they
displayed some abnormalities in the epidermis. All bone-marrow
chimeras lacked epidermal gd T cells because the hosts were
Rag1 deficient and epidermal gd T cells cannot be reconstituted
by BM from adult mice, yet only those chimeras with Ahr defi-
ciency in the nonhematopoietic compartment displayed the full
phenotype seen in Ahr-deficient mice.
Both psoriasis pathogenesis in humans and the IMQ model of
psoriasiform skin inflammation in themouse are T cell dependent
and rely on the cross-talk between adaptive immune cells and
epidermal cells. Thus, it is not surprising that in the complete
absence of effector T cells, such as in Rag1/ mice, lack of
AhR in keratinocytes did not result in increased disease severity.
IL-23-producing myeloid DCs are critical for the IMQ model,
whereas plasmacytoid DCs (pDCs) and the type I interferon
pathway are dispensable in this mouse model (Wohn et al.,
2013). We did not detect infiltration of pDCs in the skin (data
not shown) and Ahr deficiency restricted to CD11c-expressing
antigen-presenting cells did not recapitulate the hyperinflamma-
tion of Ahr/ mice, indicating that these cells, although impor-
tant for establishing inflammation in the first place, were not
drivers for the overreaction seen in Ahr/ mice. Of note is the
effect of Ahr deletion in different cell types on expression of
IL-17 and IL-22. In agreement with previous data (Martin
et al., 2009), we found that complete Ahr deficiency resulted
in higher levels of IL-17 probably due to the predominant infiltra-
tion of gd T cells, which produce more IL-17 in Ahr-deficient
mice. This effect, however, was not evident when Ahr deficiency
was restricted to T and B cells, suggesting that additional inter-
actions with other Ahr-deficient cells, e.g., APCs, contribute to
IL-17 induction. Furthermore, in contrast to our previous
demonstration that in-vitro-differentiated Th17 cells or gd
T cells require AhR stimulation for IL-22 production, IL-22 was
readily detectable in the skin of Ahr-deficient mice. It is conceiv-
able that the inflammatory milieu in the skin can provide other
factors that could override the requirement for AhR. Finally,
the systemic application of the AhR ligand FICZ caused a
reduction rather than an increase in IL-17 and IL-22. This is in
contrast to the effect of FICZ in vitro or in localized application998 Immunity 40, 989–1001, June 19, 2014 ª2014 The Authorsduring EAE, but consistent with its suppressive effect when
administered systemically (Duarte et al., 2013).The complexities
of cellular interactions in an inflammatory environment that
shape these variables require further dissection. However, in
the context of our study, we contend that IL-17 and IL-22,
although important for the development of psoriasiform inflam-
mation, are not the reason for the exacerbated response of
Ahr-deficient mice.
The IMQ model of psoriasiform skin inflammation in mice and
the pathogenesis process in psoriasis have different kinetics,
inflammatory components, and cellular mediators, but never-
theless share critical immunopathological features. Although
dispensable for the IMQmodel, both type I and II interferon path-
ways play an important role in human psoriasis (Bowcock et al.,
2001). Type I IFN is critical in the early phases of disease initiation
in a clinically relevant skin xenotransplant model where it triggers
activation and expansion of autoimmune T cells, leading to fully
fledged psoriasis plaque formation (Nestle et al., 2005).
A strong IFN-g genomic (Bowcock et al., 2001) and cellular
(Austin et al., 1999) signature is present in psoriasis, and intra-
dermal injection of IFN-g has been shown to induce several
molecular and histological features characteristic of psoriatic le-
sions in both healthy and psoriatic human skin (Johnson-Huang
et al., 2012). AHR ligation in human skin biopsies strikingly
modulated type I and II interferon pathways, particularly normal-
izing the proinflammatory signature present in L skin. On the
other hand, pharmacological blockade of the AHR pathway in
ex vivo human skin biopsies and genetic deletion of Ahr in the
mouse model resulted in an exacerbation of the inflammatory
skin signature, whereas activation of the pathway ameliorated
both.
Perhaps not surprisingly, human andmouse data did not show
mechanistic similarities in terms of genes or pathways affected
by AhR. This could be due to the very different ontogeny of the
inflammatory skin response, which is provoked by a single agent
and short lasting in the mouse, whereas it is multifactorial and
chronic in patients. In contrast, the lack of effect of AhR-medi-
ated activation on other relevant psoriasis gene signatures in
human samples, such as the antimicrobial response and tissue
remodeling, which are affected in the mouse model, could be
the result of the short-term culture of the skin biopsies. However,
both murine and human keratinocytes lacking AhR were over-
reactive to proinflammatory stimuli, suggesting shared aspects
of pathology, which may diverge later on in the chronic phase
of human psoriasis.
It remains to be clarified what the direct targets of AhR are and
how these are linked to the inflammatory networks that are
affected. The postulated extensive interaction of AhR with other
transcription factors, which may be cell type specific, presents a
substantial challenge in identifying direct as well as indirect AhR-
mediated effects in inflammatory responses. We found dysregu-
lation of the expression of the AP-1 family member Junb, which
was substantially upregulated in the inflamed skin of Ahr-defi-
cient mice and could be readily induced in in vitro keratinocytes
stimulated with IL-1b. Moreover, blocking the AP-1 pathway
dampened the increase of proinflammatory genes in Ahr-defi-
cient keratinocytes. Whereas deletion of Junb together with
Jund in mouse keratinocytes resulted in a skin phenotype
resembling psoriasis (Zenz et al., 2005), JUNB is upregulated
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meta-analysis of the psoriasis transcriptome has revealed an
enrichment of AP-1-binding sites among psoriasis-increased
genes and pinpointed the increased expression of JUNB in pso-
riasis skin to keratinocytes (Swindell et al., 2013), suggesting a
role for the AP-1 pathway and JunB as a critical checkpoint of
epidermal homeostasis.
The emerging pattern from analysis of physiological functions
of AhR in immune cell types indicates that it affects radically
different gene patterns in different cells types (Kiss et al.,
2011; Lee et al., 2012; Li et al., 2011; Nguyen et al., 2010; Qiu
et al., 2012; Veldhoen et al., 2008), suggesting that AhR may
be a modulator of gene expression with different target genes.
In keratinocytes, AhR signaling favors epidermal differentiation,
thus promoting skin barrier formation (van den Bogaard et al.,
2013) and as shown here AhR signaling exerts an anti-inflam-
matory effect in keratinocytes. More research will be needed
to identify the molecular mechanisms underlying the function
of AhR in the control of skin homeostasis during inflammatory
responses.
Under physiological conditions, AhR signaling appears to be
tightly regulated and endogenous ligands such as FICZ are
rapidly metabolized via the activity of CYP enzymes that are
downstream targets of AhR activation, most notably CYP1A1,
the main extrahepatic cytochrome p450 enzyme under control
of the AhR (Wincent et al., 2009). In fact it is now assumed that
prolonged AhR signaling in response to TCDD, for example,
causes dysregulation of its physiological functions (Bock and
Ko¨hle, 2006; Mitchell and Elferink, 2009). In keeping with this,
expression of a constitutive active form of AhR in keratinocytes
caused skin lesions (Tauchi et al., 2005), and we and others
(van den Bogaard et al., 2013) have shown beneficial conse-
quences of physiological AhR activation in skin. Interestingly,
kynureninase (KYNU), an enzyme of the tryptophan catabolism
degrading the putative AhR agonist kynurenine, is one of the
consistently upregulated genes in psoriatic skin in our data set
and in the literature (Tian et al., 2012), and other genes of the
tryptophan pathway have also been found to be differentially
regulated in psoriatic skin (Gudjonsson et al., 2010). Increased
levels of KYNU enzyme might not only reduce kynurenine levels
in psoriastic skin but also deplete tryptophan in the tissue, thus
interfering in the formation of other AhR ligands such as FICZ.
It is possible that deregulation in tryptophan catabolism
observed in psoriatic skin might decrease AhR activation and
thus result in increased expression of inflammatory mediators
in the skin. Thus, reduced levels of endogenous AhR ligands in
psoriatic skin might account for the lack of AhR-mediated
control of skin homeostasis. It is important also to consider
that dietary ligands, which are of fundamental importance in
the AhR-mediated control of intestinal homeostasis, may exert
effects in tissues other than the gastrointestinal tract. It is worth
mentioning that metabolic syndrome and Crohn’s disease are
frequently observed comorbidities of psoriasis (Davidovici
et al., 2010).
Thus, beneficial effects of AhR activation open the possibility
of therapeutic intervention in chronic inflammatory skin disease,
but further research is needed to understand the mechanism un-
derlying the physiological consequences of AhR signaling in the
immune system.EXPERIMENTAL PROCEDURES
Details on human skin biopsy culture, animals, RNA isolation, qPCR, RNA
sequencing, microarray analysis, and keratinocyte cultures are listed in Sup-
plemental Information.
Human Subjects
Lesional and nonlesional psoriasis skin biopsies were obtained from patients
of European descendent recruited at the Psoriasis Center, University Medical
Center Schleswig-Holstein, Kiel (Germany) and not receiving any systemic
treatment at the time of visit. Four skin biopsies were obtained from discarded
healthy skin from donors of European descendent undergoing plastic surgery
procedures at Guy’s and St. Thomas’ Hospital, London (UK). Full patient and
healthy control demographics are in Table S1. Our study was conducted in
accordance with the Helsinki Declaration, with written informed consent ob-
tained from each volunteer, and approved by the institutional review board
of University of Kiel Medical School and Guy’s and St. Thomas’ Hospital.
Imiquimod Model of Psoriasiform-like Skin Inflammation
Shavedmouse dorsal skin was treated daily for 5 consecutive days with 30mg
Aldara cream containing 5% Imiquimod (IMQ, Meda AB). On day 5, full-thick-
ness skin biopsies of the treated area were collected with a 8 mm biopsy
puncher; skin was either snap frozen in liquid N2 for RNA extraction, fixed in
neutral buffered formalin (Sigma) for histopathology analysis, or digested as
described below to achieve single-cell suspensions. In some experiments,
wild-type C57BL/6 mice received vehicle (olive oil) or 100 mg/kg FICZ (Enzo)
intraperitoneally on the day before starting the IMQ treatment and then daily
until the day of analysis.
Skin Histopathology
Fixed skin was embedded in paraffin and tissue sections were deparaffinized
and stained with H&E for histological analysis. Images were acquired at 310
magnification with an Olympus VS120 slide scanner. Average epidermal and
scale thickness was quantified by a researcher blind to the experimental
groups who took five measurements per three sections for each mouse.
Flow Cytometry Analysis of Skin-Infiltrating Cells
Two 8 mm punch biopsies were minced and shook in a digestion cocktail
(400 mg/ml Liberase TL [Roche] and 1 mg/ml collagenase D [Roche] in IMDM
medium) for 2 hr at 37C, then mashed through a 70 ml cell strainer. Flow
cytometry was performed with antibodies by Biolegend and cells were ac-
quired on a FACSCantoII (BD). For intracellular cytokine staining, cells were
stimulated for 4 hr with PdBU (500 ng/ml) and ionomycin (500 ng/ml) in the
presence of brefeldin A (1 mg/ml) and Fc block (BD Bioscience), while simulta-
neously stained for surface markers, then fixed with 3.8% PFA, permeabilized
with 0.1% NP-40, and stained for IL-17A and IL-22 (Biolegend).
Conditioned Medium from Skin Cell Suspension of Naive or
IMQ-Treated Wild-Type Mice
Conditioned media was obtained from supernatants of skin cell cultures from
either naive mouse skin or from skin of wild-type mice treated with IMQ
for 2 days: after obtaining single-cell suspensions as described earlier, cells
were activated with PdBU and ionomycin for 30 min at 37C in RPMI medium
supplemented with 10% fetal calf serum and 2% Pen-Strep-Gln solution
(cRPMI), washed to remove PdBU and ionomycin, and incubated in cRPMI
for 3 hr at 37C; the resulting cell-free supernatant was then used as condi-
tioned media.
Total Cellular Extract and Immunoblot
Primary keratinocytes were washed two times with ice-cold PBS and lysed
with NP40 cell lysis buffer (Life Technologies). Protein concentration was
determined by the Bio-Rad protein assay kit (Bio-Rad). Cell lysates (20 mg)
were separated by SDS-PAGE, transferred onto PVDF membranes (GE
Healthcare), and probed with a primary antibody against mouse-JunB
(1:1,000, Cell Signaling) and then with anti-rabbit immunoglobulin coupled to
peroxidase (1:10,000; GE Healthcare). The immune complexes were visual-
ized by the enhanced chemiluminescence method (Merck Millipore), and re-
sults were analyzed by Adobe Photoshop software and normalized to GAPDH.Immunity 40, 989–1001, June 19, 2014 ª2014 The Authors 999
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Statistical analysis was performed with Prism v.5.0 (GraphPad Software). For
in vivo experiments, values are expressed as themean + SEM of n animals and
data shown are representative of at least two independent experiments. Com-
parisons were calculated by unpaired t test, if two groups were assessed, or
one-way analysis of variance and Bonferroni-corrected p value for multiple
comparisons, if more than two groups were assessed. For qPCR validation
of human RNA sequencing, fold changes of treatment versus vehicle con-
trol-induced gene expression were assessed for normal Gaussian distribution
with D’Agostino & Pearson omnibus normality test and then analyzed by paired
two-tailed t test or Wilcoxon signed rank test, as appropriate and shown as
box and whiskers (Min-Max). The level of statistically significant difference
was defined as p% 0.05.
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